What are the recommended treatment options for restless legs syndrome when gabapentin cannot be used?

Treatment of Restless Legs Syndrome Without Gabapentin

Use pregabalin as your first-line pharmacological treatment when gabapentin cannot be used, with intravenous ferric carboxymaltose as an equally strong alternative if iron parameters are appropriate. 1

Primary Treatment Algorithm

Step 1: Iron Repletion (Critical First Step)

Before initiating any pharmacological therapy, assess and correct iron status:

• Check ferritin and transferrin saturation
• **If ferritin <75 ng/mL**: Initiate iron therapy with goal of ferritin >100 ng/mL 2
• Strong recommendation for IV ferric carboxymaltose in patients with appropriate iron status (moderate certainty evidence) 1
• Alternative IV options include low molecular weight iron dextran or ferumoxytol (conditional recommendations) 1
• Oral ferrous sulfate is a conditional recommendation if IV therapy unavailable (moderate certainty evidence) 1

This differs from standard iron replacement guidelines for the general population and reflects iron's critical role in RLS pathophysiology 2.

Step 2: First-Line Pharmacological Treatment (After Iron Optimization)

Pregabalin receives a strong recommendation with moderate certainty of evidence 1. This is the only remaining alpha-2-delta ligand with a strong recommendation when gabapentin/gabapentin enacarbil cannot be used.

Key advantages of pregabalin:

• Comparable efficacy to gabapentin (mean IRLS reduction ~5 points) 3
• Lower augmentation risk compared to dopaminergic agents 4
• Improves sleep quality and quality of life (SMD 0.40 and 0.33 respectively) 3

Step 3: Second-Line Options

If pregabalin is contraindicated or ineffective:

1. Dipyridamole (conditional recommendation, low certainty) 1
2. Extended-release oxycodone and other opioids (conditional recommendation, moderate certainty) 1
   • Reserve for refractory cases
   • Requires special monitoring 4
3. Bilateral high-frequency peroneal nerve stimulation (conditional recommendation, moderate certainty) 1

Step 4: Dopaminergic Agents (Use With Extreme Caution)

The 2025 AASM guidelines represent a major paradigm shift: dopamine agonists are now conditionally recommended AGAINST for standard use [@1-7@]. This change reflects recognition of augmentation as a significant long-term complication, not reduced short-term efficacy 5, 6.

If dopaminergic agents must be used (patient preference for short-term symptom reduction over long-term safety):

• Pramipexole (conditional against, moderate certainty) 1
• Ropinirole (conditional against, moderate certainty) 1
• Transdermal rotigotine (conditional against, low certainty) 1
• Levodopa (conditional against, very low certainty) 1

Critical caveat: Use only at low doses for short durations with mandatory monitoring for augmentation 2, 6.

Medications to Avoid

Strong recommendation AGAINST:

• Cabergoline (strong recommendation against, moderate certainty) 1

Conditional recommendations AGAINST:

• Bupropion 1
• Carbamazepine 1
• Clonazepam 1
• Valproic acid 1
• Valerian 1

Special Populations

End-stage renal disease patients:

• IV iron sucrose if ferritin <200 ng/mL and transferrin saturation <20% 1
• Vitamin C supplementation (conditional recommendation) 1

Common Pitfalls

1. Failing to check and optimize iron status first - This is foundational therapy, not adjunctive 2, 6
2. Starting dopamine agonists as first-line - The 2025 guidelines fundamentally changed this approach due to augmentation risk [@1-7@, 6]
3. Using inadequate pregabalin doses - Guidelines recommend higher doses of alpha-2-delta ligands compared to low-dose dopamine agonists 5
4. Not monitoring for augmentation if dopaminergic agents are used 4

Clinical Reasoning

The evidence strongly supports pregabalin when gabapentin is unavailable because: (1) it shares the same mechanism targeting α2δ calcium channels 3, (2) meta-analyses show comparable efficacy across anticonvulsants (IRLS reduction -5.12 points) 3, and (3) it avoids the augmentation risk that has relegated dopamine agonists to conditional-against status 6, 7. The 2025 AASM guidelines represent the most recent, highest-quality evidence and explicitly prioritize long-term safety and quality of life over short-term symptom control [@1-7@].